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Background: Moyamoya Disease is a rare, devastating cerebrovascular disorder characterized by stenosis/occlusion
of supraclinoid internal carotid arteries and development of fragile collateral vessels. Moyamoya Disease is typically
diagnosed by angiography after clinical presentation of cerebral hemorrhage or ischemia. Despite unclear etiology,
previous reports suggest there may be an immunological component.
Methods: To explore the role of autoimmunity in moyamoya disease, we used high-density protein arrays to
profile IgG autoantibodies from the sera of angiographically-diagnosed Moyamoya Disease patients and compared
these to healthy controls. Protein array data analysis followed by bioinformatics analysis yielded a number of auto-
antibodies which were further validated by ELISA for an independent group of MMD patients (n = 59) and control
patients with other cerebrovascular diseases including carotid occlusion, carotid stenosis and arteriovenous
malformation.
Results: We identified 165 significantly (p < 0.05) elevated autoantibodies in Moyamoya Disease, including those
against CAMK2A, CD79A and EFNA3. Pathway analysis associated these autoantibodies with post-translational
modification, neurological disease, inflammatory response, and DNA damage repair and maintenance. Using the
novel functional interpolating single-nucleotide polymorphisms bioinformatics approach, we identified 6 Moyamoya
Disease-associated autoantibodies against APP, GPS1, STRA13, CTNNB1, ROR1 and EDIL3. The expression of these 6
autoantibodies was validated by custom-designed reverse ELISAs for an independent group of Moyamoya Disease
patients compared to patients with other cerebrovascular diseases.
Conclusions: We report the first high-throughput analysis of autoantibodies in Moyamoya Disease, the results of
which may provide valuable insight into the immune-related pathology of Moyamoya Disease and may potentially
advance diagnostic clinical tools.
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Moyamoya Disease (MMD) is a rare cerebrovascular
disorder that involves progressive bilateral stenosis/
occlusion of the supraclinoid internal carotid arteries
(ICAs) as well as the proximal anterior and middle
cerebral arteries (ACAs and MCAs) [1,2]. MMD is also
characterized by the development of abnormal, fragile
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reproduction in any medium, provided the orproliferated lenticulostriate arteries [3]. Early diagnosis
is difficult and is usually made angiographically after
clinical presentation of cerebral ischemia (stroke or
TIA) or hemorrhage, often well after damage to the
brain has occurred. The etiology of MMD is currently
unknown. Approximately 10–12% of MMD cases are
clearly familial with an autosomal dominant inheritance
pattern, and several MMD-associated loci have been
identified, including 3p24.2-p26, 6q25, 8q23, 12p12,
and 17q25.3 [1,4]. Mutations in individual genes have
also been described, including TGFβ1 and PDGFRB
[5], BRCC3 [6], and RNF213 [1,4,7]. There is also some
evidence for active vascular remodeling in MMDtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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muscle cell layer in the intima of MMD vessels [1,4].
The expression levels of several proteins with known
roles in angiogenesis have been described, including
vascular endothelial growth factor (VEGF), basic fibro-
blast growth factor (bFGF) and transforming growth
factor beta (TGF-β) [1,4]. There are also reports of in-
creased intercellular adhesion molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1) in
the cerebral spinal fluid (CSF) of MMD patients [8].
MMD is often described as Moyamoya Syndrome
(MMS) when it is associated with other disorders, such
as Majewski Osteodysplastic Primordial Dwarfism Type
II (MOPD II), Down syndrome, Seckel syndrome,
Neurofibromatosis and Graves’s disease, a known auto-
immune disorder [9-11]. Although MMD is not trad-
itionally considered an autoimmune disease, several
groups have reported elevated levels of circulating
autoantibodies (autoAbs), including anti-cardiolipin [12],
anti-thyroid [13,14] and anti-α-fodrin [15]. In addition,
a SEREX profile of CSF obtained from MMD patients
identified 5 proteins against which autoAbs were
expressed [16].
To comprehensively characterize the serum autoAb rep-
ertoire in MMD patients, our unbiased approach used a
commercially-available high-density protein microarray
platform to identify circulating serum autoAbs. These
arrays have been useful for profiling disease-relevant
autoAbs and have led to the identification of novel
autoAbs in chronic renal [17], rheumatologic and auto-
immune diseases [18]. Our study identified a number of
MMD-associated autoAbs and the biological pathways
and networks associated with them.
Methods
Patients and samples
The study comprised both a discovery and a validation
phase and included 88 serum samples, 56 of which were
from MMD patients. The discovery phase involved 10
samples from healthy normal controls (mean age 29.3 ±
13.1 yrs) and 10 samples from demographically-matchedTable 1 Demographic data for control and MMD patients
Discovery set (20 sera)
Protein arrays analysis
Healthy control MM
n = 10 n = 10
Gender: males (%) 40 60
Age (yr) 29.6 ± 12.2 27.8 ± 10.7
Ethnicity% (1/2/3/4) † 30/60/10/0 20/80/0/0
(MMD) Unilateral/bilateral na 0/5
MMD =moyamoya disease; CVD = cerebrovascular disease.
†1, Caucasian; 2, Asian; 3, Hispanic 4. Other.MMD patients (mean age 27.6 ± 10.7 yrs, 5 MMD pa-
tients collected at 2 time points for each patient: pre-
operative and 6 months postoperative). AutoAbs of
interest in MMD were validated in an independent
patient cohort of 68 independent samples—46 with
MMD (mean age 40.7 ± 13.6 yrs) and 22 from matched
control patients with other cerebrovascular diseases
(CVDs) (mean age 49.1 ± 21.6 yrs) including carotid occlu-
sion (n = 8), carotid stenosis (n = 5) and arteriovenous
malformation (n = 9). MMD was radiographically defined
in all cases, with the presence of characteristic unilateral
or bilateral stenosis/occlusion of the internal carotid artery
(including involvement of the anterior cerebral artery and
the middle cerebral artery (MCA)) and the presence
of classic small caliber collateral ‘moyamoya’ vessels.
Our MMD and CVD cohort was compromised of 46%
and 52% respectively, of patients with no other clinical
condition other than cerebrovascular disease. Hyperten-
sion and hyperlipidemia were present in 24% and 40% of
the MMD and CVD cohort respectively. No patients
were clinically diagnosed with Sickle cell disease or
neurofibromatosis, nor did any have a history of cranial
x-irradiation; 2 MMD patients also had Down syndrome
however. The demographic information is summarized
in Table 1.
Using standard methods for sera collection [17], 5.0 mL
of blood from each patient was collected, and the serum
was separated by centrifugation, aliquoted and immedi-
ately stored at −80°C until use. The samples were collected
under consent at the Stanford Hospital and Clinics from
2006–2008. The study was approved by the Institutional
Review Board of Stanford University.
Immune response profiling using high-density protein
arrays
The ProtoArrayW Human Protein Microarray v4.0
(Invitrogen, Carlsbad, CA) was used to characterize
IgG reactivity in MMD. V4.0 arrays contain 8268 re-
combinant human proteins expressed as N-terminal
GST fusion proteins. We used our standard protocols
as previously described for serum sample preparation,Validation set (68 sera)
Cross sectional ELISA
D CVD control MMD
P value n = 22 n = 46 P value
0.61 45 26 0.03
0.73 49.1 ± 21.6 40.7 ± 13.6 0.10
0.66 59/36/0/5 54/28/9/9 0.45
na na 24/22 na
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[19]. Briefly, ProtoArrays were blocked with 5.0 mL
blocking buffer (100 mM sodium phosphate pH 7.4,
200 mM NaCl, 0.08% Triton X-100, 25% glycerol, 20 mM
glutathione, 1.0 mM DTT, 1.0% casein) for 1 hour at 4°C.
After the blocking step, 5.0 mL of diluted serum sample
(1:150 in PBST buffer consisting of PBS, 1% casein and
0.1% Tween 20) was applied and incubated for 90 minutes
at 4°C. The slides were washed 5 × 5 minutes with PBST
buffer prior to application of secondary antibody (anti-
human antibody-Alexa FluorW 647 conjugate). The
slides were incubated for 90 minutes at 4°C, washed for
5 × 5 minutes with PBST, dried and then scanned using
the Axon GenePix 4000B Scanner (Molecular Devices,
Sunnyvale, CA).
Data extraction
Signal intensities per spot for each individual array were
obtained using GenePix pro 6.0. We used Prospector
AnalyzerW 5.2 (Invitrogen Inc., Carlsbad, CA) to subtract
the background, and to normalize and analyze GenePix
Results (GPR) files for each array.
Data analysis for MMD-specific autoAbs
We used a standard cut-off Z-Score of 3.0. Individual
antigen reactivity was ranked based on Z-score above or
below the mean signal for each array. Arrays from pa-
tients of a distinct clinical phenotype were analyzed as a
group. Group analyses were made by comparing 2 sets
of individual antibody levels for every antigen present on
the array using M-statistics of the Prospector AnalyzerW
with the Robust-Linear-Normalization (RLM) method
[20]. Differences in significance were displayed as ANOVA
and Chebyshev’s Inequality p-Value (≤ 0.05 considered sig-
nificant). For significant autoAbs in MMD, p-value was
calculated with unpaired t-test.
To analyze MMD-associated pathways and major
functions we used Ingenuity Pathway AnalysisW (http://
www.ingenuity.com) for Global Functional Analysis (GFA)
and Global Canonical Pathways (GCP) Analysis, which
produced a list of major pathways and functions with
p-values.
Bioinformatics prediction of MMD-associated autoAbs by
functional interpolating SNPs (fitSNPs)
We used a novel data analysis method to identify MMD-
specific autoAbs by speculating that those proteins
would have a higher chance of being associated with
proteins with a higher probability of having functionally-
relevant single-nucleotide polymorphisms (SNPs). For
this purpose we used a method that employs an integra-
tion of genetic and genomic data called functional inter-
polating SNPs (fitSNPs) [21]. First, we identified three
loci (3p26-p24.2, 8q23, and 17q25) previously associatedgenetically with MMD from Online Mendelian Inherit-
ance in Man (OMIM) [22] and selected antibodies against
proteins that were significantly differentially expressed in
the serum samples of MMD patients compared to healthy
controls at the autoantibody level. Second, we sub-
selected for antibodies against proteins that in general
were highly differentially expressed across thousands of
publicly-available gene expression mRNA microarray
experiments, with a fitSNP differential expression ratio
(DER) > 0.45. Third, we identified additional proteins
that: (a) contained genetic variants associated with any
neurological diseases; (b) were significantly differentially
expressed in MMD at the autoantibody level; and (c)
were highly differentially expressed at the mRNA level
with a fitSNP DER > 0.6.
Validation of expression of MMD-associated autoAbs
Independent sera from a different cohort of MMD
patients were used for validation of the autoAbs iden-
tified in the ProtoArray discovery phase. The control
group of patients in this validation phase consisted of
age, gender and demographically-matched patients with
other causes of cerebrovascular disease, allowing an
assessment of the importance and specificity of the
autoAbs in MMD. To validate the significant autoAbs
identified by ANOVA and FitSNP analysis, we further
selected autoAbs that were known to interact with an-
tigens with biological relevance in vascular and auto-
immune disease, where the autoAbs could be detected
most easily by ELISA, and where ProtoArray measure-
ments indicated a fold change of > 2 in MMD patients.
Customized enzyme-linked immunosorbent assays (ELISAs)
were developed as previously described [17] to detect
serum immunoglobulin binding to the following array of
antigens: amyloid beta A4 protein (APP), catenin, beta 1
(CTNNB1), G protein pathway suppressor 1 (GPS1), stim-
ulated by retinoic acid 13 (STRA13), receptor tyrosine
kinase-like orphan receptor 1 (ROR1), and EGF-like re-
peats and discoidin I-like domains 3 (EDIL3). Briefly,
GST-tagged purified proteins (Invitrogen, Carlsbad, CA)
were applied to a 96-well immunosorbent plate (NUNC,
Rochester, NY) and incubated overnight at 4°C. Standard
curves for each protein were prepared using an IgG mouse
monoclonal anti-GST tag (Millipore, Temecula, CA) and
AP-conjugated AffiniPure goat anti-mouse IgG (Jackson
ImmunoResearch, West Grove, PA). The plates were
washed with TBST buffer, blocked for 1 hour at room
temperature (RT) with 2% dry milk in TBST, and incu-
bated with 50 μL of diluted serum (40-fold with 2%
dry milk in TBST buffer) for 1 hour at RT. The plates
were then washed with TBST and incubated in AP-
conjugated AffiniPure mouse anti-human IgG (Jackson
ImmunoResearch, West Grove, PA) and the reactivity
was visualized with AP-pNPP Liquid Substrate System
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measured at 405 nm with a SPECTRAMax 190 microplate
reader (Molecular Devices, Sunnyvale, CA). An unpaired
t-test p value < 0.05 was considered significant.
Results
Identification of MMD-associated autoAbs in the
discovery phase by ProtoArray analysis
MMD patients express high levels of autoAbs compared to
normal healthy controls
In the discovery phase, we evaluated sera samples col-
lected from MMD (n = 10) and healthy normal controls
(n = 10) to identify autoAbs significantly associatedTable 2 Identification of reactive antigens in MMD
Protein name
Calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha (CAMK2A
B-cell antigen receptor complex-associated protein alpha-chain
EGF-like repeats and discoidin I-like domains 3 (EDIL3)
Ectonucleoside triphosphate diphosphohydrolase 1
Proteinase 3
Calcium/calmodulin-dependent protein kinase ID (CAMK1D), transcript varian
Ephrin-A3 (EFNA3)
CD7 molecule (CD7)
Na+/K + transporting ATPase interacting 4 (NKAIN4)
CDC-like kinase 4 (CLK4)
Interferon, alpha-inducible protein 6 (IFI6)
Casein kinase 1, delta (CSNK1D), transcript variant 1
Deiodinase, iodothyronine, type III (DIO3)
Fc fragment of IgG, low affinity IIIa, receptor (CD16a) (FCGR3A)
RNA Polymerase
Uncharacterized protein C20orf96
cDNA clone MGC:31944 IMAGE:4878869, complete cds
CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1
Endoglin (Osler-Rendu-Weber syndrome 1) (ENG)
Solute carrier family 2 (facilitated glucose transporter), member 2 (SLC2A2)
Serine/threonine kinase 25 (STE20 homolog, yeast) (STK25)
Transmembrane protein 32 (TMEM32)
Chromosome 19 open reading frame 39 (C19orf39)
Calcium/calmodulin-dependent protein kinase (CaM kinase) II delta (CAMK2D
transcript variant 3
G protein pathway suppressor 1
Raptor
LPS-responsive vesicle trafficking, beach and anchor containing (LRBA)
Melanocortin 2 receptor accessory protein (MRAP), transcript variant 1
NIMA (never in mitosis gene a)-related kinase 3 (NEK3), transcript variant 1
Receptor (chemosensory) transporter protein 2 (RTP2)
The following is a subset of the most differentially expressed autoAbs increased by
MMD =moyamoya disease.
* CI p-value = Chebyshev’s Inequality p-value.(p < 0.05) with MMD. A total of 165 autoAbs were identi-
fied with a greater than 2-fold change and p ≤0.05 in
MMD compared to controls. Table 2 lists 30 of the most
significant autoAbs, while the complete list of 165
autoAbs is in Additional file 1: Table S1. Some of the
most biologically relevant autoAbs were against anti-
gens with a role in vascular and autoimmune diseases
such as: (1) calcium/calmodulin-dependent protein
kinase (CaM kinase) II alpha (CAMK2A), which is a
signaling molecule implicated in heart failure and ar-
rhythmias and is also known to phosphorylate proteins
that are responsible in processes such as excitation–
contraction coupling, cell death, and transcriptionalGene symbol CI* P- value Fold increase in MMD






























2 fold or more in MMD compared to healthy controls (p ≤ 0.05).
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cium/calmodulin-dependent protein kinase ID (CAMK1D)
transcript variant 1, which plays a role in regulating
calcium-mediated granulocyte function [24]; (3) B-cell
antigen receptor complex-associated protein alpha-
chain (CD79A), which plays a pivotal role as a B cell
antigen receptor complex [25]; (4) EGF-like repeats and
discoidin I-like domains 3 (EDIL3), which has a known
role in angiogenesis [26]; (5) ephrin-A3 (EFNA3), which
is implicated in integrin-mediated T lymphocyte inter-
actions [27] ;(6) CD7, a surface marker for CD8 T cell
effector subsets [28]; (7) Na+/K + transporting ATPase
interacting 4 (NKAIN4, c20orf58); (8) CDC-like kinase
4 (CLK4), which is a member of CLKs involved in phos-
phorylation of serine- and arginine-rich (SR) proteins;
(9) interferon alpha-inducible protein 6 (IFI6), which is
involved in apoptosis [29]; (10) casein kinase 1delta
(CSNK1D) transcript variant 1, which is involved in
DNA replication and repair [30]; and (11) Type IIIFigure 1 Increased levels of specific autoAbs were observed in MMD
Targets included (A) calcium/calmodulin-dependent protein kinase II alp
alpha-chain (CD79A); (C) G protein pathway suppressor 1 (GPS1); (D) eph
(NKAIN4); (F) Transmembrane Protein 32 (TMEM32). RFU = relative fluoreiodothyronine deiodinase (DIO3), which is involved in
thyroid hormone regulation. Figure 1 illustrates meas-
urement levels for 6 autoAbs against the following pro-
teins: CAMK2A, CD79A, G protein pathway suppressor
(GPS1), ephrin-A3 (EFNA3), Na+/K + transporting ATPase
interacting 4 (NKAIN4), and transmembrane protein
32 (TMEM32).
Ingenuity Pathway Analysis (IPA) software was applied
to all of the reactive antigens and revealed over-
represented pathways involved in Neurological Disease,
Tissue Development, Cellular Growth and Proliferation,
and Muscular System Development and Function. The
reactive antigen proteins associated with MMD in the
aforementioned pathways were: v-abl Abelson murine
leukemia viral oncogene homolog 2 (ABL2), activin A re-
ceptor, type IIA (ACVR2A), activin A receptor, type IIA
(ACVR2B), CAMK1D, calcium/calmodulin-dependent
protein kinase II alpha (CAMK2A), CAMK2D, major
histocompatibility complex, class II invariant chain (CD74),patients compared to healthy controls by protein array.
ha (CAMK2A); (B) B-cell antigen receptor complex-associated protein
rin-A3 (EFNA3); (E) Na+/K + transporting ATPase interacting 4
scence units.
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E74-like factor 2 (ELF2), endoglin (ENG), ectonucleoside
triphosphate diphosphohydrolase 1 (ENTPD1), IL2-
inducible T-cell kinase (ITK), kaptin (KPTN), LIM
domain kinase 1 (LIMK1), mitogen-activated protein
kinase kinase kinase 9 (MAP3K9), myosin light chain
kinase 2 (MYLK2), p21 protein (Cdc42/Rac)-activated
kinase 4 (PAK4), aspartoacylase (ASPA), beta-site APP-
cleaving enzyme 1 (BACE1), DEAD (Asp-Glu-Ala-Asp)
box helicase 17 (DDX17), disks large-associated protein
DLG7 (DLG7), histone deacetylase 1 (HDAC1), homer
homolog 2 (Drosophila) (HOMER2), immunoglobulin
(CD79A) binding protein 1 (IGBP1), lipoprotein lipase
(LPL), microtubule-associated protein 4 (MAP4), and
phospholipid scramblase 1 (PLSCR1). The predominant
IPA functions of these reactive antigens were Protein
Phosphorylation (p value =1.54E-07) and Protein
Modification (p value =1.84E-05), with many of the
proteins also involved in pathways deployed in Cell
Death (p value =3.74E-05). A panel of autoAbs in
MMD was also found to have reactive antigens in-
volved in Cardiac Disease, which is a frequent accom-
paniment of MMD. The increased autoAb expression
against CAMK2D is intriguing, as this protein is im-
plicated in cardiac hypertrophy and heart failure, con-
ditions which have also been reported to coexist with
MMD [31]. PRKG1, also antigenic in MMD, has been
associated with enlargement of cardiomyocytes and
smooth muscle cell proliferation [32,33]. In addition,
both LIMK1 and TNFα are associated with cardiac
stenosis, while TNFα is specifically associated with cardiac
stress response, inflammation, and fibrosis [34-36]. MMD
patients exhibited an enrichment of antigenic responses
against proteins involved in Immunological Disease and
Inflammatory Responses (p value < 2.05E-02), such as
AXL receptor tyrosine kinase (AXL), copper metabol-
ism (Murr1) domain containing 1 (COMMD1), DnaJ
(Hsp40) homolog, subfamily C, member 12 (DNAJC12)
and member 5 beta (DNAJC5B), Fc fragment of IgG,
high affinity Ia, receptor (CD64) (FCGR1A) and low
affinity IIIa, receptor (CD16a) (FCGR3A), heat shock
transcription factor 1 (HSF1), interferon, alpha-inducible
protein 27-like 2 (IFI27L2), interferon-induced protein
44-like (IFI44L), interferon, alpha 1/ interferon, alpha
13 (IFNA1/IFNA13), immunoglobulin heavy constant
mu (IGHM), immunoglobulin kappa locus (IGK@),
interleukin 20 receptor beta (IL20RB), myelin oligo-
dendrocyte glycoprotein (MOG), nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor,
epsilon (NFKBIE), NFKB repressing factor (NKRF), NLR
family, pyrin domain containing 3 (NLRP3), tumor necro-
sis factor (ligand) superfamily, member 9 (TNFSF9),
and ubiquitin-like modifier activating enzyme 7 (UBA7).
AutoAbs were also found to be highly enriched againstvascular antigens, such as angiotensinogen (AGT), MOG,
NLRP3, palmitoyl-protein thioesterase 2 (PPT2), protein
kinase C, delta (PRKCD), and SMAD family member
3 (SMAD3).A subset of autoAbs is expressed at higher levels during
the active disease state as compared to postoperative
levels in MMD patients
To determine if there was an acute-MMD autoAb pro-
file, we examined the sera of 5 MMD patients taken
prior to surgery and 6 months post-surgery. No signifi-
cant differences in the majority of MMD-related
autoAbs were detected except for 4 autoAbs that were
more highly expressed in the sera during active MMD
compared to levels 6 months post-surgery. These were
Abs against ankyrin repeat and SOCS box-containing
8 (ASB8, p = 0.02), which is known to play a role in
intracellular signal transduction [37]; a zinc transporter
solute carrier family 39 (zinc transporter) member 9
(SLC39A9, p = 0.02) [38]; and secernin 3 (SCRN3, p = 0.02)
and cytochrome P450 family 26 subfamily A polypeptide 1
(CYP26A1, p = 0.02), both of which are expressed in the
cerebral cortex [39]. It is unclear why the immune reactiv-
ity of this panel of antigens diminishes after surgical cor-
rection of the vascular stenosis. There was also a trend,
although not significant, of an increase in the postoperative
levels of the immunoglobulins IGK@, IGHM, IGHV4-31,
and IGKV1-5 (p = 0.08) compared to the active disease
state pre-surgery.Identification of MMD-associated autoAbs by fitSNP data
analysis
Six proteins were selected as significant for MMD, 3 of
which were present on MMD-associated loci. The corre-
sponding 6 mRNAs were also highly differentially
expressed in publicly-available mRNA microarray exper-
iments, across a variety of diseases with a fitSNP DER >
0.45. Our hypothesis was that these proteins may be in-
volved in the genetic basis of MMD or may be more
likely to have SNPs in the translated proteins, driving
the immunogenic autoAb response in MMD. We
further identified additional proteins that contained
genetic variants associated with neurological diseases
with cerebrovascular complications that were signifi-
cantly differentially expressed in MMD at the antibody-
level, and that were extremely highly differentially
expressed at the mRNA level with a fitSNP DER > 0.6.
The following 6 proteins were significantly associated
with MMD at the genetic, genomic and antibodyomic
level as outlined in Table 3: stimulated by retinoic acid
13 (STRA13), amyloid beta A4 protein (APP), catenin,
beta 1 (CTNNB1), G protein pathway suppressor 1
(GPS1), receptor tyrosine kinase-like orphan receptor 1
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mains 3 (EDIL3).Validation of potential autoAbs with customized indirect
ELISA assays
To further validate the significant presence of these
autoAbs identified using the fitSNPs approach, we
developed optimized indirect ELISA assays for which
reagents were commercially available. ELISA assays were
successfully performed on these 6 targets: STRA13, APP,
CTNNB1, GPS1, ROR1, and EDIL3. AutoAb expression
was examined in a set of independent MMD pre-operative
sera (n = 46) compared to cerebrovascular disease controls
(n = 22). A significant increase in autoAb levels in MMD
was confirmed by reverse ELISA for all 6 targets
as shown in Figure 2A-F: STRA13 (p = 0.01), APP
(p = 0.01), CTNNB1 (p = 0.02), GPS1 (p = 0.01), ROR1
(p = 0.04), EDIL3 (p = 0.02). Statistical analysis of the
dataset across gender revealed that the association of
AutoAb levels with gender was statistically insignificant
except for ROR1 (p = 0.03), indicating the AutoAb levels
were associated with the disease phenotype. A logistic
regression model was built on the 6 genes from ELISA
experimental data (Area Under Curve = 0.76) with 74%
sensitivity, 77% specificity, and 87% positive predictive
values (PPV) for non-invasive diagnosis of angiographically
and histologically confirmed MMD, as shown in Figure 2G.Discussion
We report the first comprehensive analysis of the pres-
ence of autoAbs in sera of MMD patients. Using high
density autoantibody arrays we identified 165 autoAbs
associated with MMD as compared to control sera. We
further identified a subset of 6 candidate MMD-specific
autoAbs, using the novel bioinformatics tool fitSNPs,
which were validated by indirect custom-designed
ELISAs in a larger cohort of MMD patients (n = 46)




APP < 0.02 Increased risk of hemorrhagic stroke, Alzheimer dise
CTNNB1 0.01 Regulation of neural progenitor cell cycle, Wnt signal
chromosome instability [43
EDIL3 0.01 Role in angiogenesis and vessel wall remodeling
ROR1 0.01 Possible role in cell migration and remodelin
GPS1 0.02 Component of the COP9 signaloso
STRA13 0.01 Component of the FA protein complex, DDR, compo
MMD-specific target proteins were identified through functional interpolating SNPs
genetic, and genomic data.
* DER = fitSNP differential expression ratio.autoAbs have not been previously associated with MMD
and their precise relationship to MMD remains un-
known. The mechanisms leading to autoantibody gener-
ation are not yet well described, although several
theories exist. These include immune responses to al-
tered protein post-translational modifications, protein
mutations and increased levels of protein expression,
either as a result of aberrant over-expression or as a
consequence of release following cellular reorganization
or damage. Ingenuity Pathway analysis, however, re-
vealed that specific pathways were over-represented by
the expressed reactive antigens, including Cell-to-Cell
Signaling and Interaction, Hematological Disease, and
Immunological Disease (Figure 3). These data make
biological sense given the nature of MMD, as it is
associated with active angiogenesis, smooth muscle
cell proliferation and tissue remodeling [1]. However,
only 21 autoAbs against antigens with previously de-
scribed functions in angiogenesis, vascular remodeling/
extracellular matrix deposition/, and vascular stability
were differentially expressed. These include endoglin
(ENG), angiomotin (AMOT) and fibroblast growth
factor receptor 1 (FGFR1), in addition to the 4 in the
subset of 6 proteins identified by fitSNP (Table 3).
Given that MMD is considered a vascular disease, this
represents a small percent of the total antigens identi-
fied in this paper. There are several possible explana-
tions for this: firstly, the antigens identified in MMD
may have as yet undefined roles in angiogenesis, are
thus not annotated as such and were not identified in
our analysis. This is certainly the case for RNF213,
which is currently not present on the array and has
only very recently been implicated in MMD and
angiogenesis [7]; secondly, the Protein Microarray
v4.0 arrays do not contain the full complement of
expressed proteins, nor are these angiogenesis-specific
arrays; finally, and perhaps most intriguingly, is the fact
that these antigens are significantly expressed both pre-










and development [46,47] 0.0003 0.484 5q14
g of cytoskeleton [48] 0.0029 0.586 1p32-p31
me, DDR [49] 0.07 0.46 17q25.3
nent of the kinetocore [50-52] 0.0021 0.581 17q25.3
approach (fitSNPs), a bioinformatics method that integrates antibodyomic,
Figure 2 Validation of autoAb expression by indirect ELISA. Six MMD-specific proteins identified through a fitSNPs approach were analyzed
by indirect ELISA for IgG levels against these antigens in MMD sera. All antigens were found to be significantly increased in MMD (n = 46)
compared to CVD controls (n = 22): (A) STRA13 (p = 0.01), (B) APP (p = 0.01), (C) CTNNB1 (p = 0.02), and (D) GPS1 (p = 0.01), (E) ROR1 (p = 0.04),
and (F) EDIL3 (p = 0.02) (OD@405 nm = optical density at 405 nm) (G) A ROC curve built on a logistic regression model using 6 autoAbs ELISA
data (Area Under Curve = 0.76) demonstrates a 74% sensitivity, 77% specificity, 87% PPV, 59% NPV and overall 75% accuracy set of all MMD
samples tested.
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more ‘angiogenic’ autoAb expression pre-surgery but
for there to be a significant decrease in these same
autoAb levels following bypass when the patients have
been treated. That autoAb levels remain high both
pre- and post-bypass surgery (ie, after the cerebral
flow had been re-established) may suggest some novel
aspect of the basic disease biology.
Of particular interest are the roles of cell cycle, DNA
maintenance and DNA damage response/repair (DDR)
pathways. Two highly expressed MMD-associated autoAbs
identified in this array with fitSNP and validated by ELISA
include those generated against COP9 signalosome
complex subunit 1 (GPS1 or CSN1) and stimulated by
retinoic acid 13 (STRA13), both of which have well-
described functions in DDR. GPS1 is a component of
the COP9 signalosome (CSN) complex whose function
is to modulate cullin neddylation, which in turn regu-
lates cullin-RING ubiquitin ligase (CRL) activity and the
ubiquitination of proteins involved in DDR [49]. The
CSN also forms complexes with CRLs containing
cullin4 in order to function in DDR, cell cycle regulationand chromatin remodeling [49]. STRA13 (also known
as CENP-X or MHF2) is the DNA-binding component
of the Fanconi Anemia (FA) core protein complex,
through its association with MHF1 and FANCM pro-
teins [50,51]. The FA complex plays a critical role in
DDR, and is specifically recruited to stalled DNA rep-
lication forks occurring as a result of blockage or
damage [53]. Two other validated MMD-specific pro-
teins, Amyloid beta A4 protein (APP) and β-catenin,
also have roles in DDR and DNA maintenance. APP, a
protein most widely studied for its role in Alzheimer
disease, has recently been identified as a component of the
TIP60 DNA repair complex, a complex that modifies
histone acetylation at DNA double strand breaks [40,41].
β-catenin has a key role in the activation of canonical
Wnt signaling and has also recently been implicated in
chromosomal instability; specifically, Aoki et al. describe
defects in β-catenin leading to activation of Wnt signal-
ing and dysregulation of the cell cycle and chromosomal
instability [43]. That DDR and DNA maintenance may
have a central role is also supported by the identification
in the discovery phase of approximately 20 autoAbs,
Figure 3 Association of MMD-specific autoAbs with a Cell-to-Cell Signaling and Interaction, Hematological Disease, and Immunological
Disease IPA network. The autoAbs validated in this study are encircled in bold red.
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and DNA maintenance, including SWSAP1, CSNK1D,
MCM10, NUDT1 and UBE2W.
Further evidence that both MMD/MMS may involve
the critical DDR comes from the recent discovery of a
novel Xq28 deletion in 3 unrelated hereditary MMS
families [6]. This deletion results in the loss of BRCC3,
an E3 ubiquitin ligase that is a subunit of the BRCA1-
BRCA2-containing complex (BRCC), and deletion of this
protein in zebrafish results in defects in angiogenesis [6].
The BRCC complex functions in DDR by stabilizing the
BRCA1 protein at DNA break points [54]. Intriguingly,
both BRCA1 and BRCA2 are also a part of the FA
complex of DDR proteins as described above [53,55].
In addition, MOPD II and Seckel syndrome, diseases
strongly associated with moyamoya angiopathy, are
sometimes caused by mutations in the pericentrin gene
[9,10,56]. Pericentrin is an essential component of the
centrosome which mediates, among others, cell cycle
progression, spindle organization and orientation, cilia
formation and DDR [57].Given that radiation exposure to the brain is one of the
leading environmental causes of moyamoya angiopathy
[58], DDR and DNA maintenance machinery may well be
compromised in MMD patients. While further research is
required to determine if this is the case, precisely how this
leads to a complex disease and syndrome remains purely
speculative. It is important to note that while defects in
DDR, chromosomal instability and cell cycle disregulation
often lead to cancer, there is no evidence of increased can-
cer rates in MMD patients, aside from an association with
NF1 [11]. DNA replication and cellular response to DNA
damage involve a vast complex of proteins and protein–
protein interactions. Given the clinical heterogeneity
of MMD and MMS, it would not be unfounded to
expect the disease to involve a spectrum of one to
several mutations in multiple genes, as is the case
with FA patients [53].
The over-representation of antigens pertaining to anti-
gen presentation, immune cell trafficking and inflamma-
tory response may also suggest a significant autoimmune
component for MMD. STRA13, one of the validated
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the stabilization of the outer kinetocore, a protein com-
plex that is essential for correct attachment, segregation
and movement of chromosomes during cell division
[52]. Reports of the expression of autoAbs to other
centromeric proteins of the kinetocore are also associ-
ated with a number of autoimmune diseases in humans
including rheumatoid arthritis and limited cutaneous
sclerosis or CREST syndrome [59]. Therefore, MMD
may be related in part to an autoimmune condition.
While the presence of autoAbs may not yet be of diag-
nostic value in MMD, this prospect may be advanced by
validating additional autoAbs and using a larger cohort
of patients. Our study demonstrates a novel role for the
autoimmune response in MMD and may provide insight
into the mechanisms of the disease, including such key
cellular processes as cell cycle and DNA repair and
maintenance. Future studies are required to further elu-
cidate the clinical relevance of these autoAbs in MMD.
There are currently no in vitro models of MMD, but re-
cent advances in disease-specific induced pluripotent
stem cells (iPSCs) may show some potential as an
in vitro model of this complex and rare disease.
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